241 related articles for article (PubMed ID: 26502687)
1. Clinical features of relapse after multidrug therapy for leprosy in China.
Shen J; Yan L; Sun P
Lepr Rev; 2015 Jun; 86(2):165-9. PubMed ID: 26502687
[TBL] [Abstract][Full Text] [Related]
2. New lesions after MDT in PB and MB leprosy: a report of 28 cases.
Kar HK; Sharma P
Indian J Lepr; 2008; 80(3):247-55. PubMed ID: 19432355
[TBL] [Abstract][Full Text] [Related]
3. A randomized controlled trial to compare cure and relapse rate of paucibacillary multidrug therapy with monthly rifampicin, ofloxacin, and minocycline among paucibacillary leprosy patients in Agra District, India.
Kumar A; Girdhar A; Girdhar BK
Indian J Dermatol Venereol Leprol; 2015; 81(4):356-62. PubMed ID: 26144850
[TBL] [Abstract][Full Text] [Related]
4. Studies on risk of leprosy relapses in China: relapses after treatment with multidrug therapy.
Chen XS; Li WZ; Jiang C; Ye GY
Int J Lepr Other Mycobact Dis; 1999 Dec; 67(4):379-87. PubMed ID: 10700911
[TBL] [Abstract][Full Text] [Related]
5. Relapses among leprosy patients treated with multidrug therapy: experience in the leprosy control program of the All Africa Leprosy and Rehabilitation Training Center (ALERT) in Ethiopia; practical difficulties with diagnosing relapses; operational procedures and criteria for diagnosing relapses.
Becx-Bleumink M
Int J Lepr Other Mycobact Dis; 1992 Sep; 60(3):421-35. PubMed ID: 1474281
[TBL] [Abstract][Full Text] [Related]
6. Changes in the size and number of skin lesions in PB leprosy on treatment and follow-up.
Rao PN; Suneetha S; Pratap DV
Lepr Rev; 2011 Sep; 82(3):244-52. PubMed ID: 22125932
[TBL] [Abstract][Full Text] [Related]
7. Long-term relapse risk of multibacillary leprosy after completion of 2 years of multiple drug therapy (WHO-MDT) in Cebu, Philippines.
Balagon MF; Cellona RV; Cruz Ed; Burgos JA; Abalos RM; Walsh GP; Saunderson PR; Walsh DS
Am J Trop Med Hyg; 2009 Nov; 81(5):895-9. PubMed ID: 19861628
[TBL] [Abstract][Full Text] [Related]
8. Clinical, bacteriological and histopathological study of 62 referral relapse cases between Jan 2004 and Dec 2009 at the Foundation for Medical Research, Mumbai.
Shetty VP; Wakade AV; Ghate SD; Pai VV
Lepr Rev; 2011 Sep; 82(3):235-43. PubMed ID: 22125931
[TBL] [Abstract][Full Text] [Related]
9. Relapses in paucibacillary leprosy after MDT--a clinical study.
Grugni A; Nadkarni NJ; Kini MS; Mehta VR
Int J Lepr Other Mycobact Dis; 1990 Mar; 58(1):19-24. PubMed ID: 2319185
[TBL] [Abstract][Full Text] [Related]
10. Combined 12-month WHO/MDT MB regimen and Mycobacterium w. vaccine in multibacillary leprosy: a follow-up of 136 patients.
Kaur I; Dogra S; Kumar B; Radotra BD
Int J Lepr Other Mycobact Dis; 2002 Sep; 70(3):174-81. PubMed ID: 12483965
[TBL] [Abstract][Full Text] [Related]
11. Risk of relapse in leprosy after fixed-duration multidrug therapy.
Li HY; Hu LF; Huang WB; Liu GC; Yuan LC; Jin Z; Li X; Li JL; Yang ZM
Int J Lepr Other Mycobact Dis; 1997 Jun; 65(2):238-45. PubMed ID: 9251597
[TBL] [Abstract][Full Text] [Related]
12. A study on the impact of FD-MDT on 200 leprosy patients.
Vara N; Marfatiya Y
Indian J Lepr; 2005; 77(3):217-27. PubMed ID: 16353520
[TBL] [Abstract][Full Text] [Related]
13. Long term follow-up results of 1 year MDT in MB leprosy patients treated with standard MDT + once a month Minocycline and Ofloxacin.
Katoch K; Katoch VM; Natarajan M; Gupta UD; Sharma VD; Singh HB
Indian J Lepr; 2008; 80(4):331-44. PubMed ID: 20329382
[TBL] [Abstract][Full Text] [Related]
14. Clinical and histopathological evaluation of the effect of addition of immunotherapy with Mw vaccine to standard chemotherapy in borderline leprosy.
Kamal R; Natrajan M; Katoch K; Arora M
Indian J Lepr; 2012; 84(4):287-306. PubMed ID: 23720894
[TBL] [Abstract][Full Text] [Related]
15. A study on the effectiveness and safety of the WHO/MDT regimen in the northeast of Thailand; a prospective study, 1984-1996.
Dasananjali K; Schreuder PA; Pirayavaraporn C
Int J Lepr Other Mycobact Dis; 1997 Mar; 65(1):28-36. PubMed ID: 9207751
[TBL] [Abstract][Full Text] [Related]
16. Clinical analysis of multibacillary leprosy patients after 1-year fixed World Health Organization recommended multidrug therapy at Yangon General Hospital, Myanmar.
Kyaw K; Tsoh TM; Swe SY; Nagaoka Y; Takezaki S; Suzuki K; Ishii N
J Dermatol; 2008 May; 35(5):264-9. PubMed ID: 18477225
[TBL] [Abstract][Full Text] [Related]
17. Relapse and deformity among 2177 leprosy patients released from treatment with MDT between 2005 and 2010 in South India: A retrospective cohort study.
Prabu R; Manickam P; Mahalingam VN; Jayasree P; Selvaraj V; Mehendale SM
Lepr Rev; 2015 Dec; 86(4):345-55. PubMed ID: 26964430
[TBL] [Abstract][Full Text] [Related]
18. Long-term efficacy of 2 year WHO multiple drug therapy (MDT) in multibacillary (MB) leprosy patients.
Cellona RV; Balagon MF; dela Cruz EC; Burgos JA; Abalos RM; Walsh GP; Topolski R; Gelber RH; Walsh DS
Int J Lepr Other Mycobact Dis; 2003 Dec; 71(4):308-19. PubMed ID: 14763888
[TBL] [Abstract][Full Text] [Related]
19. Fixed-duration multidrug therapy in multibacillary leprosy.
Li HY; Hu LF; Wu PW; Luo JS; Liu XM
Int J Lepr Other Mycobact Dis; 1997 Jun; 65(2):230-7. PubMed ID: 9251596
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of multidrug therapy in multibacillary leprosy: a long-term follow-up of 34 multibacillary leprosy patients treated with multidrug regimens till skin smear negativity.
Shaw IN; Christian M; Jesudasan K; Kurian N; Rao GS
Lepr Rev; 2003 Jun; 74(2):141-7. PubMed ID: 12862255
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
